AIM(S): This study assessed the effect of differences in renal function on the pharmacokinetics and pharmacodynamics of dapagliflozin, a renal sodium glucose co-transporter-2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus (T2DM). METHODS: A single 50 mg dose of dapagliflozin was used to assess pharmacokinetics and pharmacodynamics in five groups: healthy non-diabetic subjects; patients with T2DM and normal kidney function and patients with T2DM and mild, moderate or severe renal impairment based on estimated creatinine clearance. Subsequently, 20 mg once daily multiple doses of dapagliflozin were evaluated in the patients with T2DM. Formation rates of dapagliflozin 3-O-glucuronide (D3OG), an inactive metabolite, were evaluated using human isolated kidney and liver microsomes. RESULTS: Plasma concentrations of dapagliflozin and D3OG were incrementally increased with declining kidney function. Steady-state Cmax for dapagliflozin were 4%, 6% and 9% higher and for D3OG were 20%, 37% and 52% higher in patients with mild, moderate and severe renal impairment, respectively, compared with normal function. AUC(0,τ) was likewise higher. D3OG formation in kidney microsomes was three-fold higher than in liver microsomes and 109-fold higher than in intestine microsomes. Compared with patients with normal renal function, pharmacodynamic effects were attenuated with renal impairment. Steady-state renal glucose clearance was reduced by 42%, 83% and 84% in patients with mild, moderate or severe renal impairment, respectively. CONCLUSIONS: These results indicate that both kidney and liver significantly contribute to dapagliflozin metabolism, resulting in higher systemic exposure with declining kidney function. Dapagliflozin pharmacodynamics in diabetic subjects with moderate to severe renal impairment are consistent with the observation of reduced efficacy in this patient population.
AIM(S): This study assessed the effect of differences in renal function on the pharmacokinetics and pharmacodynamics of dapagliflozin, a renal sodium glucose co-transporter-2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus (T2DM). METHODS: A single 50 mg dose of dapagliflozin was used to assess pharmacokinetics and pharmacodynamics in five groups: healthy non-diabetic subjects; patients with T2DM and normal kidney function and patients with T2DM and mild, moderate or severe renal impairment based on estimated creatinine clearance. Subsequently, 20 mg once daily multiple doses of dapagliflozin were evaluated in the patients with T2DM. Formation rates of dapagliflozin 3-O-glucuronide (D3OG), an inactive metabolite, were evaluated using human isolated kidney and liver microsomes. RESULTS: Plasma concentrations of dapagliflozin and D3OG were incrementally increased with declining kidney function. Steady-state Cmax for dapagliflozin were 4%, 6% and 9% higher and for D3OG were 20%, 37% and 52% higher in patients with mild, moderate and severe renal impairment, respectively, compared with normal function. AUC(0,τ) was likewise higher. D3OG formation in kidney microsomes was three-fold higher than in liver microsomes and 109-fold higher than in intestine microsomes. Compared with patients with normal renal function, pharmacodynamic effects were attenuated with renal impairment. Steady-state renal glucose clearance was reduced by 42%, 83% and 84% in patients with mild, moderate or severe renal impairment, respectively. CONCLUSIONS: These results indicate that both kidney and liver significantly contribute to dapagliflozin metabolism, resulting in higher systemic exposure with declining kidney function. Dapagliflozin pharmacodynamics in diabetic subjects with moderate to severe renal impairment are consistent with the observation of reduced efficacy in this patient population.
Authors: Mark E Molitch; Ralph A DeFronzo; Marion J Franz; William F Keane; Carl Erik Mogensen; Hans-Henrik Parving Journal: Diabetes Care Date: 2003-01 Impact factor: 19.112
Authors: John P H Wilding; Vincent Woo; Norman G Soler; Andrea Pahor; Jennifer Sugg; Katja Rohwedder; Shamik Parikh Journal: Ann Intern Med Date: 2012-03-20 Impact factor: 25.391
Authors: Sreeneeranj Kasichayanula; Xiaoni Liu; Weijiang Zhang; Marc Pfister; Frank P LaCreta; David W Boulton Journal: Clin Ther Date: 2011-10-26 Impact factor: 3.393
Authors: René Santer; Martina Kinner; Christoph L Lassen; Reinhard Schneppenheim; Paul Eggert; Martin Bald; Johannes Brodehl; Markus Daschner; Jochen H H Ehrich; Markus Kemper; Salvatore Li Volti; Thomas Neuhaus; Flemming Skovby; Peter G F Swift; Jürgen Schaub; Dan Klaerke Journal: J Am Soc Nephrol Date: 2003-11 Impact factor: 10.121
Authors: Michael A Nauck; Stefano Del Prato; Juris J Meier; Santiago Durán-García; Katja Rohwedder; Martina Elze; Shamik J Parikh Journal: Diabetes Care Date: 2011-08-04 Impact factor: 19.112
Authors: Tamara Y Milder; Sophie L Stocker; Dorit Samocha-Bonet; Richard O Day; Jerry R Greenfield Journal: Eur J Clin Pharmacol Date: 2019-08-03 Impact factor: 2.953
Authors: Matthew M Riggs; Leo J Seman; Alexander Staab; Thomas R MacGregor; William Gillespie; Marc R Gastonguay; Hans J Woerle; Sreeraj Macha Journal: Br J Clin Pharmacol Date: 2014-12 Impact factor: 4.335
Authors: Sreeneeranj Kasichayanula; Xiaoni Liu; Frank Lacreta; Steven C Griffen; David W Boulton Journal: Clin Pharmacokinet Date: 2014-01 Impact factor: 6.447
Authors: Kathleen M Knights; Shane M Spencer; John K Fallon; Nuy Chau; Philip C Smith; John O Miners Journal: Br J Clin Pharmacol Date: 2016-03-14 Impact factor: 4.335
Authors: K Melissa Hallow; Peter J Greasley; Gabriel Helmlinger; Lulu Chu; Hiddo J Heerspink; David W Boulton Journal: Am J Physiol Renal Physiol Date: 2018-07-18